The value analysis of tumor deposit in the comprehensive evaluation before differentiated thyroid cancer RAI therapy

Lei Wang, Jing Yang, Yuan Zhu, Zhiyong LiFrontiers in Oncology 2025 · DOI

TL;DR

This study identifies tumor deposits (TD)—discrete tumor nodules found in fat or soft tissue—as a significant independent prognostic factor for differentiated thyroid cancer (DTC). The researchers demonstrate that the presence of TD significantly reduces the efficacy of radioactive iodine (RAI) therapy and propose "upgrading" the clinical staging for TD-positive patients to better reflect their actual risk.

What Problem Does This Paper Address?

In the management of differentiated thyroid cancer (DTC), clinicians rely on staging systems like the TNM (Tumor, Node, Metastasis) and the American Thyroid Association (ATA) risk stratification to predict recurrence and decide on treatments like radioactive iodine (RAI) therapy. However, these systems may be missing a key piece of the puzzle: Tumor Deposits (TD).

TDs are discrete tumor nodules found in the tissue surrounding the primary tumor that lack the identifiable structure of a lymph node. While their prognostic importance is well-established in colorectal and gastric cancers, their role in thyroid cancer has remained murky. This paper investigates whether TDs impact how well a patient responds to RAI therapy and asks a critical question: Should the presence of TD change a patient's official cancer stage?

Methods

The researchers conducted a retrospective analysis of 11,278 surgical thyroid cancer patients treated between 2019 and 2023. To ensure a fair comparison, they used Propensity Score Matching (PSM), a statistical technique that creates a "balanced" comparison group. They matched 106 TD-positive patients with 106 TD-negative patients who had nearly identical baseline characteristics (age, T stage, etc.).

The primary outcome measured was an "Excellent Response" (ER) to RAI therapy, defined by clean imaging and very low levels of thyroglobulin (a protein marker for thyroid tissue). They used Cox proportional hazards models to determine if TD was an independent predictor of treatment success.

Datasets

  • Primary Cohort: 11,278 thyroid cancer surgical patients from The Affiliated Hospital of Xuzhou Medical University.
  • Prognostic Dataset: 2,162 patients eligible for long-term follow-up (2,056 TD-negative; 106 TD-positive).
  • Matched Dataset: 212 patients (106 per group) used for the final comparative analysis after PSM.

Key Insights and Ideas

  • TD as a "Silent" Risk Factor: Even when patients appear to have similar disease burdens based on traditional staging, the presence of TD significantly lowers the likelihood of a successful response to RAI.
  • The "Stage Migration" Effect: The most significant finding is that TD-positive patients "behave" like patients in a more advanced disease category. For instance, a patient with TD in the central lymph nodes (N1a) has a prognosis statistically similar to a patient with more aggressive lateral lymph node involvement (N1b) who lacks TD.
  • Refining Risk Stratification: The study suggests the current ATA "Intermediate Risk" category is too broad. TD-positive patients in this group have outcomes that mirror the "High Risk" group, suggesting they may require more aggressive initial treatment or closer monitoring.

Key Results

  • Prevalence: TDs were found in 2.08% of the total thyroid cancer population studied.
  • Impact on Treatment Success: In the intermediate-risk group, only 35.4% of TD-positive patients achieved an "Excellent Response," compared to 67.4% of TD-negative patients (P = 0.013).
  • Prognostic Equivalence:
    • TD-positive patients in N1a stage had a similar prognosis to TD-negative patients in N1b stage (P = 0.867).
  • TD-positive patients in TNM Stage I had a similar prognosis to TD-negative patients in TNM Stage II (P = 0.338).
  • TD-positive ATA Intermediate-risk patients had a similar prognosis to TD-negative ATA High-risk patients (P = 0.300).
  • Independent Predictor: Multivariate analysis confirmed that the presence of TD is an independent prognostic factor (Hazard Ratio for achieving ER was 0.24, meaning TD-positive patients were significantly less likely to reach a disease-free state).

Limitations and Future Work

The authors acknowledge that this was a single-center retrospective study, which can introduce selection bias. Additionally, the number of patients in certain subgroups (like those with TD but no lymph node involvement, pN0) was quite small, limiting the statistical power for those specific cases.

The researchers call for multicenter prospective studies to validate these findings. If confirmed, these results could lead to a formal update in international staging guidelines, officially incorporating tumor deposits into the TNM and ATA systems for thyroid cancer.

Summary updated

Abstract

TD should be considered as a prognostic factor in the postoperative RAI treatment. We propose incorporating TD into the TNM staging and the ATA initial risk stratification system as a reference, suggesting that TD-positive patients in N1a stage be classified as N1b stage; patients in TNM stage I be classified as TNM stage II ;and the ATA intermediate risk patients be classified as the ATA high risk.
BibTeX
@inproceedings{wang2025value,
  author = {Lei Wang and Jing Yang and Yuan Zhu and Zhiyong Li},
  title = {{The value analysis of tumor deposit in the comprehensive evaluation before differentiated thyroid cancer RAI therapy}},
  booktitle = {Frontiers in Oncology},
  year = {2025},
  doi = {10.3389/fonc.2025.1593603},
}
Figure